

Emergency contact information:

Emergency Prescriber Contact:

Telephone number during office hours:

Telephone number after office hours:

Further information is available in the patient brochure.

Information for Patients and Healthcare Professionals

Lenalidomide is structurally related to thalidomide and is expected to cause severe birth defects or death to an unborn baby therefore:

- Female patients of childbearing potential must always use effective contraception
- Female patients of childbearing potential must have pregnancy tests every 4 weeks, prior to each prescription, to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation
- Male patients with pregnant partners or partners of childbearing potential not using effective contraception must always use condoms (even if man has had a vasectomy)
- If a female patient or female partner of a male patient suspects they are pregnant, they must contact their prescriber immediately
- You **MUST** tell your prescriber immediately if you experience any symptoms that causes concern.

For complete information on the side effects of lenalidomide, patients should read the Package Leaflet and HCPs should read the Summary of Product Characteristics.

Information for Healthcare Professionals:

Prescription details

Has the patient received counselling?:	Yes/No
Childbearing potential assessment:	WCBP / WNCBP / Male
If the patient is a WCBP is she using effective contraception?	Yes/No
If the patient is male, is he using condoms, if required?	Yes/No

A completed Prescription Authorisation Form must accompany each prescription to confirm that the patient continues to use effective contraception (if required) and, in the case of a WCBP, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant.

Information for Healthcare Professionals:

Prescription details

This patient is receiving lenalidomide for treatment of:	
	Multiple Myeloma or
	Myelodysplastic Syndromes or
	Mantle Cell Lymphoma or
	Follicular Lymphoma

MHRA approval date 20/05/2021
BBBB2838